230 related articles for article (PubMed ID: 17395611)
1. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
[TBL] [Abstract][Full Text] [Related]
2. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
[TBL] [Abstract][Full Text] [Related]
3. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.
Hirooka Y; Itoh A; Kawashima H; Hara K; Nonogaki K; Kasugai T; Ohno E; Ishikawa T; Matsubara H; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Yamamoto K; Kaneko T; Nieda M; Yokokawa K; Goto H
Pancreas; 2009 Apr; 38(3):e69-74. PubMed ID: 19276867
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
[TBL] [Abstract][Full Text] [Related]
5. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
[TBL] [Abstract][Full Text] [Related]
7. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.
Dauer M; Herten J; Bauer C; Renner F; Schad K; Schnurr M; Endres S; Eigler A
J Immunother; 2005; 28(4):332-42. PubMed ID: 16000951
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
Pei Q; Pan J; Zhu H; Ding X; Liu W; Lv Y; Zou X; Luo H
Int Immunopharmacol; 2014 Mar; 19(1):10-6. PubMed ID: 24389382
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
[TBL] [Abstract][Full Text] [Related]
11. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Smith PL; Yogaratnam Y; Samad M; Kasow S; Dalgleish AG
Clin Transl Oncol; 2021 Jan; 23(1):110-121. PubMed ID: 32661823
[TBL] [Abstract][Full Text] [Related]
12. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
13. Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
Zhu XJ; Yang ZF; Zhou JY; Liu L; Sun XM; Fan ZF; Hu SY; Chen YC; Li WX; Cao M; Wang LX
PLoS One; 2015; 10(7):e0132799. PubMed ID: 26181041
[TBL] [Abstract][Full Text] [Related]
14. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.
Schneider C; Schmidt T; Ziske C; Tiemann K; Lee KM; Uhlinsky V; Behrens P; Sauerbruch T; Schmidt-Wolf IG; Mühlradt PF; Schmidt J; Märten A
Gut; 2004 Mar; 53(3):355-61. PubMed ID: 14960515
[TBL] [Abstract][Full Text] [Related]
15. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
[TBL] [Abstract][Full Text] [Related]
16. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.
De Sanctis F; Sandri S; Martini M; Mazzocco M; Fiore A; Trovato R; Garetto S; Brusa D; Ugel S; Sartoris S
Vaccine; 2018 Jun; 36(25):3708-3716. PubMed ID: 29752021
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model.
Shangguan A; Shang N; Figini M; Pan L; Yang J; Ma Q; Hu S; Eresen A; Sun C; Wang B; Velichko Y; Yaghmai V; Zhang Z
Cytotherapy; 2020 Jan; 22(1):6-15. PubMed ID: 32005355
[TBL] [Abstract][Full Text] [Related]
19. Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer.
Little EC; Wang C; Watson PM; Watson DK; Cole DJ; Camp ER
J Surg Res; 2012 Aug; 176(2):359-66. PubMed ID: 22221605
[TBL] [Abstract][Full Text] [Related]
20. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
Shevchenko I; Karakhanova S; Soltek S; Link J; Bayry J; Werner J; Umansky V; Bazhin AV
Int J Cancer; 2013 Jul; 133(1):98-107. PubMed ID: 23233419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
